Compare FDMT & ISD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDMT | ISD |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.4M | 483.8M |
| IPO Year | 2020 | N/A |
| Metric | FDMT | ISD |
|---|---|---|
| Price | $7.98 | $14.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $34.29 | N/A |
| AVG Volume (30 Days) | ★ 747.3K | 127.1K |
| Earning Date | 02-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.69% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,000.00 | N/A |
| Revenue This Year | $21,227.03 | N/A |
| Revenue Next Year | $161.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 605.88 | N/A |
| 52 Week Low | $2.24 | $10.98 |
| 52 Week High | $12.34 | $13.17 |
| Indicator | FDMT | ISD |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 61.97 |
| Support Level | $7.30 | $14.26 |
| Resistance Level | $7.80 | $14.61 |
| Average True Range (ATR) | 0.53 | 0.12 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 55.27 | 100.00 |
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.